Do Obesity and Overweight Influence Disease Activity Measures in Axial Spondyloarthritis? A Systematic Review and Meta-Analysis

被引:25
作者
Ortolan, Augusta [1 ]
Lorenzin, Mariagrazia [1 ]
Felicetti, Mara [1 ]
Ramonda, Roberta [1 ]
机构
[1] Univ Padua, Padua, Italy
关键词
BODY-MASS INDEX; ACTIVITY SCORE ASDAS; ANKYLOSING-SPONDYLITIS; CLASSIFICATION CRITERIA; BACK-PAIN; IMPROVEMENT; BURDEN;
D O I
10.1002/acr.24416
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective The aim of our systematic review and meta-analysis was to investigate whether overweight/obesity are associated with higher disease activity measures in patients with axial spondyloarthritis (SpA). Methods MEDLINE, PubMed, and Web of Science were searched using key terms corresponding to population (axial SpA patients), exposure (overweight/obesity), and outcome (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Ankylosing Spondylitis Disease Activity Score [ASDAS]). Predefined inclusion criteria were adult patients with axial SpA, exposure classified according to body mass index (BMI), BASDAI/ASDAS reported for each BMI group, and observational studies. The Newcastle-Ottawa Scale for cohort, cross-sectional, and case-control studies was used for quality check. Random-effects meta-analysis was used to pool results, which were expressed as the mean difference (MD) in BASDAI and ASDAS between BMI groups, with 95% confidence intervals (95% CIs). Results A total of 10 articles were included in the meta-analysis. The MD in BASDAI between normal BMI and overweight/obese patients was -0.38 (95% CI -0.56, -0.21; P < 0.0001); the MD in ASDAS between the same groups was -0.19 (95% CI -0.29, -0.09; P < 0.0001). The MD in BASDAI between normal BMI and overweight patients was -0.09 (95% CI -0.33, 0.15; P = 0.45), and the MD between normal BMI and obese patients was -0.78 (95% CI -1.07, -0.48; P < 0.0001). For ASDAS, the MD between normal BMI and overweight patients was -0.02 (95% CI -0.19, 0.15; P = 0.79), and the MD between normal BMI and obese patients was -0.42 (95% CI -0.60, -0.23; P < 0.0001). Conclusion Overweight and obese patients with axial SpA tend to present higher disease activity scores compared to patients with a normal BMI. This difference seems to be clinically meaningful only for the comparison between obese patients and patients with normal BMI, and more for BASDAI than ASDAS.
引用
收藏
页码:1815 / 1825
页数:11
相关论文
共 39 条
[1]
Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old [J].
Adams, Kenneth F. ;
Schatzkin, Arthur ;
Harris, Tamara B. ;
Kipnis, Victor ;
Mouw, Traci ;
Ballard-Barbash, Rachel ;
Hollenbeck, Albert ;
Leitzmann, Michael F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (08) :763-778
[2]
Effect of HLA-B27 Status and Body Mass Index on the Clinical Response to Infliximab in Ankylosing Spondylitis Patients [J].
Al-Osami, Mohammed Hadi ;
Hameed, Ekhlas Khalid ;
Al-Hamadani, Ali Mohammed .
INDIAN JOURNAL OF RHEUMATOLOGY, 2018, 13 (01) :33-37
[3]
Aydin M, 2014, CLIN INVEST MED, V37, pE186
[4]
Bakirci S, 2020, CLIN EXP RHEUMATOL, V38, P144
[5]
Braun J, 2014, CLIN EXP RHEUMATOL, V32, pS96
[6]
THE EUROPEAN-SPONDYLARTHROPATHY-STUDY-GROUP PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SPONDYLARTHROPATHY [J].
DOUGADOS, M ;
VANDERLINDEN, S ;
JUHLIN, R ;
HUITFELDT, B ;
AMOR, B ;
CALIN, A ;
CATS, A ;
DIJKMANS, B ;
OLIVIERI, I ;
PASERO, G ;
VEYS, E ;
ZEIDLER, H .
ARTHRITIS AND RHEUMATISM, 1991, 34 (10) :1218-1227
[7]
Increased Body Mass Index in Ankylosing Spondylitis Is Associated with Greater Burden of Symptoms and Poor Perceptions of the Benefits of Exercise [J].
Durcan, Laura ;
Wilson, Fiona ;
Conway, Richard ;
Cunnane, Gaye ;
O'Shea, Finbar D. .
JOURNAL OF RHEUMATOLOGY, 2012, 39 (12) :2310-2314
[8]
Validity of Self-report Screening for Overweight and Obesity Evidence from the Canadian Community Health Survey [J].
Elgar, Frank J. ;
Stewart, Jennifer M. .
CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2008, 99 (05) :423-427
[9]
Erol K, 2018, ACTA REUMATOL PORT, V43, P32
[10]
GARRETT S, 1994, J RHEUMATOL, V21, P2286